Pfizer and Astellas announced the final results of the overall analysis from Phase 3 PROSPER study. The trial enrolled adults with with non-metastatic castration-resistant prostate cancer (nmCRPC). The study evaluated Xtandi plus androgen deprivation therapy (ADT) versus placebo plus ADT.
The risk of death reduced by 27% in Xtandi plus ADT compared to placebo plus ADT. The median OS was 67.0 months compared to 56.3 months in placebo plus ADT arm.
GSK presented the results of DREAMM-2 and DREAMM-6 data in relapsed/refractory multiple myeloma patients.
In DREAMM-2 study, median overall survival was 14.9 months and median duration of response was 11 months.
In DREAMM-6 study, belantamab mafodotin plus bortezomib and dexamethasone resulted in 78% overall response rate.
Roche presented the ALEX study results for patients with ALK-positive non-small cell lung cancer. The trail is intended to confirm the long-term efficacy of Alcensa.
In ALEX study, the overall survival at five years is 62.5 % in Alecensa arm compared to 45.5% in crizotinib arm.
Novartis presented the overall survival benefit of its blockbuster product, Kisqali. The company has presented MONALEESA-7 (M7) and MONALEESA-3 (M3) subgroup analysis.
The study confirmed that patients who were administered with Kisqali had extended life compared to normal endocrine therapy. The reduction in death was ~47% and 37% in M7 and M3 studies respectively.